dalteparin sodium

ApprovedSmall molecule

Pfizer

dalteparin sodium is one of 37 small molecule programs targeting Thrombophlebitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombophlebitisActive, not recruiting

Venous ThromboembolismActive, not recruiting

ThrombophiliaActive, not recruiting

ThrombophlebitisApproved

Active, not recruiting

Venous ThromboembolismApproved

Active, not recruiting

ThrombophiliaPhase 3

Active, not recruiting

Competition

Competitive Landscape

78 competitors in Venous Thromboembolism

#DrugCompanyPhaseTrials

Pradaxa

Boehringer Ingelheim

Phase 3

4 2

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 3

Fragmin

Pfizer

Phase 2

9 4

Unfractionated Heparin

GSK

Phase 3

3 5

Low-Molecular-Weight Heparin

Daiichi Sankyo

Phase 3

3 6

BAY 987519

Bayer

Phase 3

1 7

REGN7508

Regeneron

Phase 3

1 8

Dabigatran Dose 2

Boehringer Ingelheim

Phase 3

8 9

dalteparin sodium

Pfizer

Approved

2 10

YM150

Astellas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Clinical

Trials by Indication[1]

Venous Thromboembolism2 trials

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

Completed·—·N/A·NCT01050153·50 enrolled

Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00655122·8 enrolled

Prophylaxis2 trials

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

Completed·OOttawa Hospital Research Institute·Phase 3·NCT01274637·62 enrolled

Thrombophilia1 trial

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

Completed·OOttawa Hospital Research Institute·Phase 3·NCT00967382·292 enrolled

Thrombosis1 trial

Treatment of Upper Extremity Deep-Vein Thrombosis

Completed·UUniversity of Oklahoma·Phase 4·NCT00245856·67 enrolled

Thrombophlebitis1 trial

Management of Superficial Thrombophlebitis

Completed·UUniversity of Oklahoma·Phase 4·NCT00264381·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for dalteparin sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dalteparin sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dalteparin sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

dalteparin sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Venous Thromboembolism2 trials

Prophylaxis2 trials

Thrombophilia1 trial

Thrombosis1 trial

Thrombophlebitis1 trial

References

Drug Info

Quick Facts

Related News